BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Sunovion Pharmaceuticals Inc. Presents Results From a One-year, Large Simple Safety Study of BROVANA® (arformoterol tartrate) Inhalation Solution


5/20/2013 10:23:33 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced results of a one-year, non-inferiority clinical trial that evaluated BROVANA® (arformoterol tartrate) Inhalation Solution versus placebo for the risk of serious respiratory events (respiratory death or COPD-related hospitalizations due to exacerbations) in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The study results, which were presented in three posters at the American Thoracic Society (ATS) International Conference in Philadelphia, showed that of 420 patients treated with BROVANA, 40 experienced at least one serious respiratory event as compared to 63 patients who experienced at least one serious respiratory event of the 421 receiving placebo. Among those patients who experienced an event, the mean time to first event was longer for BROVANA patients (171.7 days) as compared to patients receiving placebo (155 days).

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES